(MENAFN- ProactiveInvestors - N.America) CEL-SCI Corporation (NYSEMKT:CVM) shares fell by a third on Tuesday after the company said it received verbal notice from the US Food and Drug Administration that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold.
Patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed.
CEL-SCI was also told to expect a formal letter from the FDA within 30 days and will work with the FDA to obtain the release of the clinical hold.
The study currently has about 926 patients enrolled.
CEL-SCI shares were down 32.7% at $0.29 on Tuesday.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.